Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

kyverna therapeutics inc - KYTX

KYTX

Close Chg Chg %
10.23 -0.62 -6.06%

Open Market

9.61

-0.62 (6.06%)

Volume: 224.35K

Last Updated:

Apr 23, 2026, 9:58 AM EDT

Trade Now

Company Overview: kyverna therapeutics inc - KYTX

KYTX Key Data

Open

$10.23

 Day Range

9.56 - 10.26

52 Week Range

1.92 - 13.67

 Market Cap

$586.87M

Shares Outstanding

60.44M

 Public Float

35.02M

Beta

2.64

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.66

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.07M

  

KYTX Performance

1 Week
 
 3.02%
 
1 Month
 
 31.15%
 
3 Months
 
 4.82%
 
1 Year
 
 387.14%
 
5 Years
 
 N/A
 

KYTX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Kyverna Therapeutics Inc - KYTX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - 7.03M
-
Sales Growth
- - +24.20% -100.00%
-
Cost of Goods Sold (COGS) incl D&A
1.05M 1.71M 2.13M 1.80M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.05M 1.71M 2.13M 1.80M
Depreciation
1.05M 1.71M 2.13M 1.80M
Amortization of Intangibles
- - - -
-
COGS Growth
+79.35% +62.42% +24.96% -15.66%
Gross Income
5.97M (1.71M) (2.13M) (1.80M)
Gross Income Growth
+17.83% -128.57% -24.96% +15.66%
Gross Profit Margin
- - - +85.04%
-
2022 2023 2024 2025 5-year trend
SG&A Expense
35.36M 60.70M 140.47M 167.38M
Research & Development
27.35M 48.22M 110.34M 131.27M
Other SG&A
8.01M 12.48M 30.13M 36.11M
SGA Growth
+12.55% +71.67% +131.42% +19.16%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 648.00K
-
EBIT after Unusual Expense
(29.38M) (62.41M) (142.60M) (169.83M)
Non Operating Income/Expense
556.00K 2.23M 15.27M 9.01M
Non-Operating Interest Income
565.00K 2.28M 15.36M 9.09M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
65.00K 187.00K 142.00K 489.00K
Interest Expense Growth
+2,066.67% +187.69% -24.06% +244.37%
Gross Interest Expense
65.00K 187.00K 142.00K 489.00K
Interest Capitalized
- - - -
-
Pretax Income
(28.89M) (60.37M) (127.48M) (161.31M)
Pretax Income Growth
-9.65% -108.93% -111.17% -26.54%
Pretax Margin
- - - -411.29%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(28.89M) (60.37M) (127.48M) (161.31M)
Minority Interest Expense
- - - -
-
Net Income
(28.89M) (60.37M) (127.48M) (161.31M)
Net Income Growth
-9.65% -108.93% -111.17% -26.54%
Net Margin Growth
- - - -411.29%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(28.89M) (60.37M) (127.48M) (161.31M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(28.89M) (60.37M) (127.48M) (161.31M)
EPS (Basic)
-0.6701 -1.4001 -3.3254 -3.6445
EPS (Basic) Growth
-9.64% -108.94% -137.51% -9.60%
Basic Shares Outstanding
43.12M 43.12M 38.33M 44.26M
EPS (Diluted)
-0.6701 -1.4001 -3.3254 -3.6445
EPS (Diluted) Growth
-9.64% -108.94% -137.51% -9.60%
Diluted Shares Outstanding
43.12M 43.12M 38.33M 44.26M
EBITDA
(28.33M) (60.70M) (140.47M) (167.38M)
EBITDA Growth
-9.99% -114.23% -131.42% -19.16%
EBITDA Margin
- - - -403.32%
-

Snapshot

Average Recommendation BUY Average Target Price 29.60
Number of Ratings 6 Current Quarters Estimate -0.77
FY Report Date 06 / 2026 Current Year's Estimate -3.053
Last Quarter’s Earnings -0.77 Median PE on CY Estimate N/A
Year Ago Earnings -3.64 Next Fiscal Year Estimate -2.977
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 6 6 6
Mean Estimate -0.77 -0.76 -3.05 -2.98
High Estimates -0.65 -0.51 -2.44 -2.31
Low Estimate -0.90 -0.94 -3.70 -3.75
Coefficient of Variance -11.38 -20.04 -15.68 -19.45

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Kyverna Therapeutics Inc in the News